Aggressive fibromatosis

被引:55
作者
Fisher, Cyril [1 ]
Thway, Khin [1 ]
机构
[1] Royal Marsden Hosp, London SW3 6JJ, England
关键词
GASTROINTESTINAL STROMAL TUMOR; FAMILIAL ADENOMATOUS POLYPOSIS; BETA-CATENIN EXPRESSION; DESMOID TUMORS; DEEP FIBROMATOSIS; DEDIFFERENTIATED LIPOSARCOMA; CLINICOPATHOLOGICAL ANALYSIS; IMATINIB; THERAPY; SARCOMA;
D O I
10.1097/PAT.0000000000000045
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Aggressive (deep or desmoid-type) fibromatoses are locally infiltrative collagen-forming tumours with potential for recurrence but not metastasis. They exert their clinical effects primarily in relation to location and have variable biological behaviour. In sporadic cases there are somatic mutations in the b-catenin (CTNNB1) gene on 3p21, resulting in immunohistochemically demonstrable overexpression in nuclei. Fibromatosis in patients with familial adenomatous polyposis (FAP) harbours inactivating germline mutations in the desmoid region of the adenomatous polyposis coli (APC) gene on 5q21-q22. The differential diagnosis includes other myofibroblastic lesions, perineurioma, low grade fibromyxoid sarcoma and, in the abdomen, gastrointestinal stromal tumour and liposarcoma with 'low-grade' dedifferentiation. The primary management is surgical, though some desmoids cease to grow and can be watched. Other therapies have a role in stabilising growth or shrinking tumours. Although no single therapy is effective in all cases, available modalities including irradiation, hormonal therapy, chemotherapy, and receptor tyrosine kinase inhibition can be of value in appropriate clinicopathological subgroups. © 2013 Royal College of Pathologists of Australasia.
引用
收藏
页码:135 / 140
页数:6
相关论文
共 84 条
  • [11] Whole-exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors
    Chmielecki, Juliann
    Crago, Aimee M.
    Rosenberg, Mara
    O'Connor, Rachael
    Walker, Sarah R.
    Ambrogio, Lauren
    Auclair, Daniel
    McKenna, Aaron
    Heinrich, Michael C.
    Frank, David A.
    Meyerson, Matthew
    [J]. NATURE GENETICS, 2013, 45 (02) : 131 - 132
  • [12] Efficacy of Imatinib in Aggressive Fibromatosis: Results of a Phase II Multicenter Sarcoma Alliance for Research through Collaboration (SARC) Trial
    Chugh, Rashmi
    Wathen, J. Kyle
    Patel, Shreyaskumar R.
    Maki, Robert G.
    Meyers, Paul A.
    Schuetze, Scott M.
    Priebat, Dennis A.
    Thomas, Dafydd G.
    Jacobson, Jon A.
    Samuels, Brian L.
    Benjamin, Robert S.
    Baker, Laurence H.
    [J]. CLINICAL CANCER RESEARCH, 2010, 16 (19) : 4884 - 4891
  • [13] Clark SK, 1998, BRIT J SURG, V85, P970
  • [14] Colombo C, 2012, HISTOL HISTOPATHOL, V27, P641, DOI 10.14670/HH-27.641
  • [15] Advanced aggressive fibromatosis: Effective palliation with chemotherapy
    Constantinidou, Anastasia
    Jones, Robin L.
    Scurr, Michelle
    Al-Muderis, Omar
    Judson, Ian
    [J]. ACTA ONCOLOGICA, 2011, 50 (03) : 455 - 461
  • [16] Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis
    Constantinidou, Anastasia
    Jones, Robin L.
    Scurr, Michelle
    Al-Muderis, Omar
    Judson, Ian
    [J]. EUROPEAN JOURNAL OF CANCER, 2009, 45 (17) : 2930 - 2934
  • [17] Clinical Outcomes of Systemic Therapy for Patients With Deep Fibromatosis (Desmoid Tumor)
    de Camargo, Veridiana Pires
    Keohan, Mary L.
    D'Adamo, David R.
    Antonescu, Cristina R.
    Brennan, Murray F.
    Singer, Samuel
    Ahn, Linda S.
    Maki, Robert G.
    [J]. CANCER, 2010, 116 (09) : 2258 - 2265
  • [18] Cytogenetic, clinical, and morphologic correlations in 78 cases of fibromatosis:: A report from the CHAMP study group
    De Wever, I
    Dal Cin, P
    Fletcher, CDM
    Mandahl, N
    Mertens, F
    Mitelman, F
    Rosai, J
    Rydholm, A
    Sciot, R
    Tallini, G
    Van den Berghe, H
    Vanni, R
    Willén, H
    [J]. MODERN PATHOLOGY, 2000, 13 (10) : 1080 - 1085
  • [19] Estrogen receptor-β expression in extraabdominal fibromatoses -: An analysis of 40 cases
    Deyrup, AT
    Tretiakova, M
    Montag, AG
    [J]. CANCER, 2006, 106 (01) : 208 - 213
  • [20] MUC4 Is a Highly Sensitive and Specific Marker for Low-grade Fibromyxoid Sarcoma
    Doyle, Leona A.
    Moeller, Emely
    Dal Cin, Paola
    Fletcher, Christopher D. M.
    Mertens, Fredrik
    Hornick, Jason L.
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2011, 35 (05) : 733 - 741